Authors: | Crump, C. J.; Castro, S. V.; Wang, F.; Pozdnyakov, N.; Ballard, T. E.; Sisodia, S. S.; Bales, K. R.; Johnson, D. S.; Li, Y. M. |
Article Title: | BMS-708,163 targets presenilin and lacks notch-sparing activity |
Abstract: | The "Notch-sparing" γ-secretase inhibitor (GSI) BMS-708,163 (Avagacestat) is currently in phase II clinical trials for Alzheimer's disease. Unlike previously failed GSIs, BMS-708,163 is considered to be a promising drug candidate because of its reported Notch-sparing activity for the inhibition of Aβ production over Notch cleavage. We now report that BMS-708,163 binds directly to the presenilin-1 N-terminal fragment and that binding can be challenged by other pan-GSIs, but not by γ-secretase modulators. Furthermore, BMS-708,163 blocks the binding of four different active site-directed GSI photoaffinity probes. We therefore report that this compound acts as a nonselective γ-secretase inhibitor. © 2012 American Chemical Society. |
Keywords: | clinical trial; protein binding; hela cells; drug design; drug synthesis; chemistry; amino terminal sequence; sulfonamides; receptors, notch; clinical trials, phase ii as topic; biochemistry; catalytic domain; protein cross linking; alzheimer disease; amyloid precursor protein secretases; presenilin 1; photoaffinity labeling; presenilins; alzheimer's disease; in-phase; amyloid beta-protein precursor; alkyne; n-terminals; secretases; avagacestat; photoaffinity; drug candidates; oxadiazoles |
Journal Title: | Biochemistry |
Volume: | 51 |
Issue: | 37 |
ISSN: | 0006-2960 |
Publisher: | American Chemical Society |
Date Published: | 2012-09-18 |
Start Page: | 7209 |
End Page: | 7211 |
Language: | English |
DOI: | 10.1021/bi301137h |
PROVIDER: | scopus |
PUBMED: | 22931393 |
PMCID: | PMC3470910 |
DOI/URL: | |
Notes: | --- - "Export Date: 1 October 2012" - "CODEN: BICHA" - "Source: Scopus" |